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Several labdane diterpenes exert anti-inﬂammatory and cytoprotective actions; therefore, we have investigated whether these
molecules protect cardiomyocytes in an anoxia/reperfusion (A/R) model, establishing the molecular mechanisms involved inthe
process. The cardioprotective activity of three diterpenes (T1, T2 and T3) was studied in the H9c2 cell line and in isolated rat
cardiomyocyte subjected to A/R injury. In both cases, treatment with diterpenes T1 and T2 protected from A/R-induced
apoptosis, as deduced by a decrease in the percentage of apoptotic and caspase-3 active positive cells, a decrease in the
Bcl-2/Bax ratio and an increase in the expression of antiapoptotic proteins. Analysis of cell survival signaling pathways showed
that diterpenes T1 and T2 added after A/R increased phospho-AKT and phospho-ERK 1/2 levels. These cardioprotective effects
were lost when AKT activity was pharmacologically inhibited. Moreover, the labdane-induced cardioprotection involves
activation of AMPK, suggestingaroleforenergyhomeostasis intheir mechanism ofaction.Labdane diterpenes(T1 andT2) also
exerted cardioprotective effects against A/R-induced injury in isolated cardiomyocytes and the mechanisms involved activation
of speciﬁc survival signals (PI3K/AKT pathways, ERK1/2 and AMPK) and inhibition of apoptosis.
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Cardiac injury due to ischemia (anoxia)/reperfusion (I(A)/R) is
caused by two main mechanisms, apoptosis and necrosis,
the latter being accelerated by reperfusion.
1–5 Knowledge of
molecular mechanisms involved in A/R reveals that cardio-
protection is afforded by activation during reperfusion of the
anti-apoptotic and prosurvival kinase signaling cascades
PI3K-AKT and p42/p44 extracellular signal-regulated kinases
(ERK1/2).
6,7 Early activation of ERK1/2 inhibits procaspase
processing and induces the expression of proteins of the anti-
apoptotic Bcl-2 family (Bcl-2 and Bcl-xL). Thus, therapeutic
strategiesthattargetandattenuatereperfusion-inducedinjury
may provide novel pharmacological agents, which can be
used in current early reperfusion maneuvring, the established
standard therapy for acute myocardial infarction. As no drugs
to reduce reperfusion injury are currently available for clinical
use,
8 it is interesting to search for new interventions
administered at the time of reperfusion.
Bioactive natural products can be considered as very
promising molecules for the development of new therapeutic
agents and terpenes, which constitute one of the groups
with great therapeutic potential.
9–12 In particular, diterpenes
have shown a broad spectrum of biological acti-
vities (antibacterial, antiviral, anti-inﬂammatory, cytotoxic,
antitumour, etc), regulating inﬂammation and the innate
immune response.
13–17 Our previous ﬁndings on the anti-
inﬂammatory and cytoprotective effects of diterpenes
9,10,14
prompted us to evaluate a possible therapeutic intervention
for cardioprotection (to ameliorate A/R injury). In the present
study, we have analyzed targets relevant to the reperfusion
injury in an A/R model in cardiomyocytes in order to explore
the mechanisms involved in the cardioprotective potential of
three labdane diterpenes (Figure 1a). Our data show that two
of thesediterpenes (T1 and T2) exert signiﬁcant cardioprotec-
tion against A/R injury through inhibition of apoptosis and
activation of survival pathways.
Results
The labdane diterpenes T1 and T2 protected H9c2 cells
from A/R-induced apoptosis. We ﬁrst examined the
viability of H9c2 cells after treatment with diterpenes
(0–100mM), using an MTT assay. As seen in Figure 2a,
these diterpenes did not signiﬁcantly affect cell viability at
concentrations below 20mM, and this dose was selected as
the maximal concentration for the subsequent studies. Initial
experiments using the experimental protocol shown in
Received 28.7.11; revised 21.9.11; accepted 04.10.11; Edited by RA Knight
1DepartamentodeFarmacologı ´a,FacultaddeFarmacia,UniversidadComplutensedeMadrid,Madrid,Spainand
2InstitutodeInvestigacionesBiome ´dicas‘AlbertoSols’
(CSIC-UAM), Madrid, Spain
*Corresponding authors: L Bosca ´, Instituto de Investigaciones Biome ´dicas ‘Alberto Sols’ (CSIC-UAM), Arturo Duperier 4, 28029 Madrid, Spain.
Tel: þ34 9149 72747; Fax: þ34 9158 54401; E-mail: lbosca@iib.uam.es
or B de las Heras, Departamento de Farmacologı ´a, Facultad de Farmacia, Universidad Complutense
de Madrid, Plaza Ramo ´n y Cajal s/n, 28040 Madrid, Spain. Tel: þ34 9139 42276; Fax: þ34 9139 41726; E-mail: lasheras@farm.ucm.es
Keywords: labdane diterpenes; apoptosis; AKT; ERK; AMPK; cardioprotection
Abbreviations: A/R, anoxia/reperfusion; AMPK, AMP-kinase; DMSO, dimethyl sulfoxide; ATCC, American Type Culture Collection; ERK, extracellular signal
regulated-kinase; JNK, c-Jun N-terminal kinase; LDH, lactate dehydrogenase; MAPK, mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinase; qRT-PCR,
quantitative real-time (RT) polymerase chain reaction (PCR); SDS-PAGE, sodium dodecyl sulphate polyacrylamide gel electophoresis; T1, (dehydroisohispanolone);
T2, (8,9-dehydrohispanolone 15,16-lactol); T3, (14,15,16-trisnor-13,9a-hispanolide)
Citation: Cell Death and Disease (2011) 2, e229; doi:10.1038/cddis.2011.113
& 2011 Macmillan Publishers Limited All rights reserved 2041-4889/11
www.nature.com/cddisFigure 2b were designed to determine the time course in the
loss of cell viability after A/R-dependent injury (Figure 2c).
A/R caused a marked increase of LDH activity in the culture
medium, an index of myocyte injury (Figure 2d). Addition of
diterpenes T1 and to a lesser extent of T2 at 20mM for 4h
and 6h during reoxygenation, signiﬁcantly reduced the levels
of LDH released in response to A/R, whereas T3 was
inactive. Figure 2e shows the dose-dependent protection
exerted by T1 and T2 at 6h after reoxygenation and Figure 2f
shows the loss of protection when the diterpenes were added
late after reoxygenation.
The number of apoptotic cells, which were detected as
TUNEL-positive nuclei, signiﬁcantly decreased in cardio-
myocytes exposed to A/R and incubated with T1 during
reoxygenation (6h), and to a lesser but signiﬁcant extent with
T2 (Figure 2g, left). Agreement was observed between the
TUNELdataandthepercentageofcellswithactivecaspase-3
as determined by the CaspGlow assay (Figure 2g, right).
Quantitative analysis of these data is shown in Figure 2h.
Similar data were obtained when the effects of the diterpenes
T1 and T2 on caspase-3 activity and protein content were
determined using speciﬁc caspase substrates and antibodies
(Figures 2I and J).
T1 and T2 modulated early signaling favoring an
antiapoptotic response after A/R challenge. We next
studied the effects of the diterpenes on proteins involved in
survival and apoptotic pathways. In this analysis, expression
of proapoptotic proteins such as Bax was markedly
increased 6h after A/R, but remained unchanged in cells
treated with T1 and T2. In contrast, anti-apoptotic proteins
(Bcl-2 and Bcl-xL) exhibited lesser regulation. Moreover, the
levels of Hsp70 and the inhibitory protein xIAP also increased
after treatment of cells with diterpenes for 6h after A/R
(Figure 3a). The Bax/Bcl-2 ratio increased in H9c2 cells
after A/R compared with normoxic cells, and this increase
was signiﬁcantly impaired by treatment with T1 and T2
(Figure 3a), all these data suggesting that these compounds
favor an antiapoptotic proﬁle.
AKT and ERK activation are involved in the protective
effects of T1 and T2. Previous results led us to investigate
early signaling involved in apoptosis regulation, in particular
AKT and MAPKs activities, and the energetic metabolism
modulated through AMPK. An initial analysis revealed
that both diterpenes induced a time-dependent increase
(up to 1h) in the levels of phospho-AKT in cells incubated
with T1 and T2 (Figure 3b). Moreover, addition of T1 and T2
after A/R also induced phosphorylation of AKT (both in S473
and T308), an effect suppressed by pretreatment with a PI3K
inhibitor (LY294002) and/or AKT inhibitor (Figure 3c).
Interestingly, inhibition of the PI3K pathway attenuated the
effects of T1 on A/R-induced upregulation of Bax and on
the active caspase-3 levels. Inhibition of AKT suppressed the
protective effects exerted by T1 (Figure 3c). In addition,
measurement of caspase-3 activity and cell viability
conﬁrmed the relevance of the AKT and to a lesser extent
of the PI3K pathways in mediating the effects of T1 after A/R
(Figure 3d). MAPKs have been reported to modulate
apoptosis in the heart.
18,19 We therefore examined the
activation state of the distinct MAPK pathways to assess
their potential involvement in the cardioprotective actions
of the diterpenes. A signiﬁcant basal phosphorylation of
ERK1/2 was observed in H9c2 cells exposed to A/R.
However, incubation of cells with T1 and T2 resulted in a
marked activation of ERK phosphorylation after A/R,
whereas the total protein expression of this kinase
remained constant. In contrast, the levels of phospho-p38
were unaffected. As seen in Figure 3e, phospho-JNK was not
modulated at the times of sampling. To point out, from an
energetic aspect, phospho-AMPK levels were enhanced by
diterpenes after A/R.
When other stimuli apart from A/R were used to induce
apoptosis (H2O2, etoposide or staurosporine) the protective
effects of diterpenes T1 and T2 were not observed (Figure 4).
Minimal protection by T1 and T2 was found against H2O2,
but not against etoposide and staurosporine, suggesting a
speciﬁc protection against A/R injury by these diterpenes.
T1 and T2 protected primary cultures of rat
cardiomyocyte against A/R injury. To conﬁrm the cardio-
protective effects of diterpenes T1 and T2 observed in H9c2
cells, we moved to primary cultures of rat cardiomyocytes
subjected to A/R, following the same protocol as above.
Addition of T1 and T2 signiﬁcantly protected cardiomyocytes
against A/R-induced injury, as deduced by the decrease in
the release of LDH to the culture medium; again, T3 showed
a weak activity (Figure 5a). Treatment with T1 and T2 also
impaired pro-caspase-3 processing after A/R (Figure 5b).
Expression of Bax following A/R was also attenuated in cells
treated with diterpenes, whereas Bcl-2 and xIAP levels
remained unaffected (Figure 5b).
The cardioprotective effects exerted by diterpenes in H9c2
cells involved an increase of phosphorylated AKT, ERK1/2
and AMPK levels that were conﬁrmed in isolated cardiomyo-
cytes (Figures 5c and d). Phospho-p38 levels were moder-
ately increased after A/R regardless of the presence of the
diterpenes and phospho-JNK remained dephosphorylated.
(Figure 5d).
Discussion
Protection of the heart from I(A)/R injury still represents a
great challenge in the search for new pharmacological
agents.
20–22 Myocardial ischemia is due to blockage of the
blood ﬂow in the myocardium, leading to a signiﬁcant change
in the energy balance including depletion of ATP. A
Figure 1 Chemical structure of the labdane diterpenes. Chemical structures of
the labdane diterpenes derived from the hispanolone (T1, T2 and T3)
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Cell Death and Diseasecompensatory response emerges in the cardiomyocytes from
the inhibition of fatty acid oxidation to an increase in the ﬂux
toward anaerobic glycolysis.
4,5,23,24 Although the drop in ATP
during ischemia inhibits several basic cell processes, includ-
ing membrane sodium/potassium-ATPase, reperfusion of the
myocardium triggers a rapid increase in intracellular calcium
that promotes opening of the mitochondrial permeability
transition pore leading to the release of proapoptotic
mediators and reactive oxygen species that are key factors
in cardiac dysfunction.
25 In this scenario, we have evaluated
the role of labdane diterpenes, members of the bicyclic
diterpenoid group, that are potent anti-inﬂammatory mole-
cules in immune cells and also exhibit cell-protective
effects.
13Inpreviousstudies,weanalyzedaseriesoflabdane
diterpenes, some of them showing potent anti-inﬂammatory
activity by decreasing the release of inﬂammatory mediators
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Figure 2 Labdane diterpenes protect H9c2 cells from A/R-induced injury. (a) Viability of H9c2 cells incubated for 24h with diterpenes (0–100mM), measured by the MTT
assay.(b)Schematicdiagramoftheexperimental protocol(T: diterpenes).(c)Time-dependenteffectofreoxygenationon cellviability(MTTassay).(d)LDHreleaseafterA/R
(4–6h).Diterpeneswereaddedpriorreoxygenation.100%LDHactivitywasachievedafteradditionof0.5%TritonX-100tothecellculture.**Po0.01treatmentsversusTriton
X-100. (e) Dose-dependent effect of diterpenes on cell viability at 6h after A/R. (f) Effect of delayed-addition of diterpenes after A/R. Cell viability was determined by the MTT
assayat 6h after reoxygenation and expressed as cell viability (%) versusnormoxic cells. (g) TUNEL positive cells (left) and caspase active positivecells (right) expressed as
percentage of total cells in diterpene-treated cells versus non-treated cells. **Po0.01 compared versus A/R in the absence of diterpene. (h) In situ evaluation of caspase-3
activation.Thepercentageofcaspase-3positivecellswasdeterminedbyﬂuorescencemicroscopyusingtheCaspGlowstainingkit.(i)Caspase-3activityand(j)proteinlevels
of pro-caspase-3 and active caspase-3 were determined in cytosolic extracts from cells after A/R and treated with diterpenes T1 and T2. Lane charge was normalized with
b-actin. Western blots were performed in triplicate. Results show the mean±S.D. of three experiments. **Po0.01 treatments versus A/R in the absence of diterpene
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Cell Death and Disease(NO, PGE2, cytokines) through inhibition of NF-kB activity.
14
A selection of these diterpenes showing good chemical
stability, low toxicity and potent (T2 and T3) or negligible
(T3) anti-inﬂammatory activity have been evaluated in the
present work. To our knowledge no other studies have
examined the potential of labdane diterpenes for cardiopro-
tection. There are a few that describe a protective role
for natural products, such as antioxidant polyphenols,
22,26,27
and by the triterpene saponins.
28,29 In the present study, we
have focused on the molecular mechanisms underlying the
effects of labdanes to protect cardiomyocytes against
A/R-induced injury. These diterpenes did not affect cell
viability at concentrations lower than 20mM, and T1 proved
to be safe when used up to 50mM for at least 48h.
Cardiomyocyte loss after ischemia is mainly due to
apoptosis, necrosis (when the cell is unable to support the
apoptotic energetic demands), or commitment to autophagy
in an attempt to rescue cell function,
21,23,30,31 all three cell-
fateshaving animportant role inthe heart after I(A)/R-induced
dysfunction. Indeed, prevention of the apoptosis induced by
ischemia or anoxia minimizes cardiac injury. Our data on
early apoptotic signaling after A/R shows that T1 and T2
protect against cytochrome c release from the mitochondria
(not shown), impair Bax accumulation and upregulate the
Figure 3 DiterpenesT1andT2promoteAKTandERKactivationandfavortheBcl-2familyantiapoptoticproteinsproﬁle.(a)LevelsofHsp70,Bax,Bcl-2,xIAPandBcl-xL
were determined by western blot from cytosolic extracts from diterpene-treated cells. Protein loading was normalized with b-actin. The Bax/Bcl-2 ratio was determined at 6h
after reoxygenation. (b) Time-course of phosphorylation of AKT was determined under normoxic conditions and after A/R. Representative western blots were performed with
cytosolic extracts from cells treated with T1 and T2. The samples were immunoblotted and probed with anti-phospho-T308-AKT and anti-phospho-S473-AKT antibodies or
anti-AKT antibody as a loading control. (c) Levels of phospho-T308-AKT, Bax and caspase-3 were also determined in the presence or absence of AKT inhibitor, LY294002
and/or T1, using b-actin as a loading control. (d) Densitometry of caspase-3 activity levels in the presence or absence of AKT inhibitor, LY294002 and/or diterpene T1.
(e) Regulation of MAPKs (ERK, p38, JNK) and AMPK. Results show representative blots and the mean±S.D. out of three experiments. *Po0.05; **Po0.01 treatments
versus A/R in the absence of diterpene
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Cell Death and Diseaselevels of the antiapoptotic proteins xIAP, Bcl-2 and Bcl-xL. In
agreement with these data the processing and activity of pro-
caspase-3wasabrogatedafterA/RbyT1andT2,andanend-
point of apoptosis, such as TUNEL assays conﬁrmed the
protective role of the diterpenes. Interestingly, the protection
exerted by T1 and T2 persisted even when these labdanes
were administered 1 hour after reoxygenation (less than 15%
reductionincellviabilityat6h)suggestingasigniﬁcantdegree
of reversibility in cardiomyocyte injury, when they are added
soon after A/R.
A large number of studies have shown that PI3K/AKT
signaling pathways provide an important cell survival
signal for cardiomyocytes.
7,32–34 In our study, phospho-AKT
levels were enhanced by T1 and T2 under basal normoxic
conditions, and the phosphorylation in T308 and S473
persisted at least for 1 hour. Under A/R conditions, this
phosphorylation was even enhanced and selective inhibition
of PI3K or AKT prevented protection by T1 as deduced by the
rise in Bax levels and caspase-3 processing and activation,
leading to a drastic loss in cardiomyocyte viability. In addition
to this, treatment with T1 and T2 also regulated MAPKs
phosphorylation in cardiomyocytes exposed to A/R, as shown
by increased levels of phospho-ERK1/2 (anti-apoptotic) in
early reperfusion. However, the levels of p38 that are related
to a more proapoptotic condition remained elevated versus
the normoxic condition despite the presence of T1 and T2.
The levels of phospho-JNK remained unchanged after A/R
and minimally decreased when cells were treated with T1 and
T2. Indeed, JNK activation appears to be an important stress
kinaseintheheartandwhenactivated,canleadtodetrimental
effects via pro-inﬂammatory signaling and recruitment
of immune cells.
19 These results were conﬁrmed in rat
cardiomyocytes where diterpenes T1 and T2 exerted similar
cardioprotective effects through the mentioned survival path-
ways.
Finally, cardiomyocytes after I(A)/R are facing a metabolic
failureandthereisagrowingbodyofevidencesuggestingthat
AMPK activation has a relevant cardioprotective func-
tion.
24,31,35 Our data shows a signiﬁcant activation of AMPK
after A/R both in the cardiomyocyte cell line and especially in
isolated cardiomyocytes. Although the mechanism governing
this process by T1 is being studied, the data clearly points out
to a process activated post anoxia and following reoxygena-
tion, which has potential complementary interventions in this
pathway that is under continuous pharmacological progress.
In agreement with these observations, transgenic mice
expressing a kinase dead form of AMPK that were subjected
to low-ﬂow ischemia and reperfusion (I/R) showed signiﬁcant
impairment of glucose uptake, glycolysis and fatty acid
oxidation.
36
Taken together, our data describe an efﬁcient protection of
cardiomyocytes by T1 and T2 after A/R and provide new
insights to understand the cardioprotective mechanism of
labdane diterpenes. Moreover, ischemic heart precondi-
tioning is one of the strategies to improve clinical outcomes
in patients with coronary heart disease. The presence of
molecules improving cell viability, such as the diterpenes
described in this work, deserves additional focus.
5 In this
context,thelowcytotoxicity ofthesecompoundsincellculture
and their effectiveness in a rat cardiomyocytes A/R model
indicates that these labdane diterpenes have potential use in
Figure 4 Effect of diterpenes on apoptosis induced by H2O2, etoposide and staurosporine. Cells were pre-incubated with diterpenes (20mM) for 30min and exposed
for 18h to different concentrations of H2O2, etoposide, staurosporine or vehicle. Cell viability was evaluated by the MTT assay. Results show the mean±S.D. out of four
experiments. *Po0.05; ** Po0.01 treatments versus the vehicle condition
Figure 5 Diterpenes exert cardioprotective effects in isolated rat cardiomyo-
cytes after A/R through inhibition of apoptosis and activation of survival pathways.
(a) LDH release in the supernatants of diterpene-treated rat cardiomyocytes after
A/R (mean±S.D.; n¼4; *Po0.05, ** Po0.01 treatments versus Triton X-100 as
100%). Representative western blot analysis (n¼3–4 experiments) showing the
effects of diterpenes on (b) apoptosis-related proteins (cleaved caspase-3, Bax,
Bcl-2 and xIAP), (c) levels of phosphorylated AKT and (d) MAPKs (ERK, p38 and
JNK) and AMPK in total extracts obtained from rat cardiomyocytes exposed to A/R
at 6h after reoxygenation. Western blots were performed in triplicate
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Cell Death and Diseasethe treatment of cardiovascular diseases, and provide
useful tools for the development of chemopreventive and
chemotherapeutic strategies.
Materials and Methods
Materials. DiterpenesT1(dehydroisohispanolone),T2 (8,9-dehydrohispanolone
15,16-lactol) and T3 (14,15,16-trisnor-13,9a-hispanolide) were obtained from
hispanolone as previously described.
37–39
Dulbecco’s modiﬁed Eagle’s medium (DMEM) was purchased from ATCC
(AmericanTypeCultureCollection).Therestofculturereagentswereobtainedfrom
Invitrogen (Alcobendas, Spain). Western blot reagents were obtained (purchased)-
from GE Healthcare (Buckinghamshire, UK). Antibodies were obtained (purchased)
from the following suppliers: anti-ERK, anti-pERK, anti-JNK, anti-pJNK, anti-p38,
anti-pp38, anti-AKT, anti-pAKT(S-473), anti-pAKT (T-308), anti-AMPK, anti-
pAMPK, anti-caspase-3 (Cell Signaling Technologies, Beverly, MA, USA); anti-
Hsp70 (Gen Script, Piscataway, NJ, USA); anti-Bax, anti-xIAP (BD Biosciences,
San Jose, CA, USA); anti-Bcl2, anti-Bcl-xL (Santa Cruz Biotech., Santa Cruz, CA,
USA). The ﬂuorescent kit for TUNEL was from Roche (Mannheim, Germany). The
CaspGLOW ﬂuorescein active caspase-3 staining kit was obtained (purchased)
from BioVision Research (San Francisco, CA, USA) and the speciﬁc ﬂuorogenic
substrate for caspase-3 was obtained (purchased) from BD Biosciences. Type II
collagenase was from Worthington (Lakewood, NJ, USA). LY294002 and kinase
inhibitors were obtained (purchased) from Cell Signaling.
Cell culture. H9c2 embryonic rat heart-derived cells were obtained from ATCC.
The cells were cultured in DMEM with 10% fetal bovine serum (FBS), 100U/ml
penicillin, and 100mg/ml streptomycin, and maintained in 5% CO2 at 371C. When
cell conﬂuence was reached, cells were subcultured by detaching with 0.05%
trypsin-EDTAandreseeding.Forexperiments,cellsweremaintainedinDMEMplus
2% FBS.
Isolation of cardiac myocytes was performed as previously described.
40 Adult
mate Wistar rats were heparinized (4U/g) and anaesthetized with sodium
pentobarbital (50mg/kg). The hearts were removed and mounted on a Langerdorff-
perfusion apparatus. The ascending aorta was cannulated and a retrograde
perfusion was set up. The hearts were successively perfused with the following
oxygenated solutions at 361C: (1) standard nominally Ca
2þ-free Tyrode solution
(3min), (2) standard nominally Ca
2þ-free Tyrode solution (15min) containing
60U/ml of type II collagenase. The hearts were removed from the Langerdorff
apparatus, and after removal of atria, the ventricles were cut off and gently shaken
for 3min in a standard Tyrode solution containing 0.1mM CaCl2 to disperse the
isolated cells. The resulting cell suspensions were ﬁltered through a 250mm nylon
mesh and centrifuged for 4min at 20g. Finally, the cell pellets were maintained as
the H9c2 cells in the presence of 0.1mM CaCl2.
Anoxia/reoxygenation (A/R) protocol. To mimic an I/R model
(via anoxia in the medium), cells at 80% conﬂuence were incubated with a
glucose-free medium (previously bubbled with 95% N2 and 5% of CO2) for 3h at
371C in a hypoxic chamber (95% N2 and 5% CO2). For A/R studies, the medium
was then replaced by maintenance medium (DMEM with 2% FBS) during the
reoxygenation period. Diterpenes (20mM unless otherwise indicated) were then
added to the cells for 4 or 6h.
Cell viability and apoptosis assays. Cell viability was determined by the
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay following
the method described by Mossman.
41 Cells were seeded at a density of
3 10
4cells/well in 96-well plates and were incubated with MTT (5mg/ml) for
2h at 371C. After that, the medium was removed and DMSO (100ml) was added
into each well. The optical density (OD) was determined spectrophotometrically
at 540nm.
Lactatedehydrogenaseactivity(LDH)wasdeterminedinthecellculturemedium
by measuring the conversion of pyruvate to lactate. LDH activity was analyzed
spectrophotometrically at 340nm. The activity of the LDH in the supernatants
was compared with the ‘total content’ in cells disrupted by treatment with 0.5%
Triton X-100.
Caspase-3 activity was spectroﬂuorometrically determined in cytosolic protein
extracts using a speciﬁc substrate (Ac-DEVD-AMC) for this caspase, according
to the supplier’s instructions (BD Biosciences).
In vivo activation of caspase-3 in apoptotic cells was measured by ﬂuorescence
microscopy after labeling the cells with the caspase-3 inhibitor DEVD-FMK
conjugatedto FITC(FITC-DEVD-FMK)as amarker,followingtheinstructionsof the
supplier of the CaspGLOW ﬂuorescein active caspase-3 staining kit (BioVision
Research).
For detection and quantiﬁcation of apoptosis, the terminal deoxynucleotidyl
transferase-mediated dUTP nick end-labeling (TUNEL) assay was performed
according to the manufacturer’s instructions using a commercially available kit for
death detection (Roche). H9c2 cells were seeded at a density of 10
4cells/well into
sterile 8-well Chamber Slides (Falcon, Brookings, SD, USA), exposed to A/R and
treated with diterpenes. After reoxygenation (6h) cells were ﬁxed with 4%
p-formaldehyde for 15min. Cells were then permeabilized in ice-cold methanol and
incubated with 3% bovine serum albumin (BSA) for 30min. Coverslips were
mounted in Prolong Gold antifade reagent (Invitrogen) and examined using an
Espectral Leica TCS SP25 confocal microscope (Leica, Solms, Germany). Alexa
ﬂuorescence was excited by the 488nm line of an Argon laser 11 and emission
collected through a BP ﬁlter (505–530nm). DAPI ﬂuorescence was excited by the
Hg lamp (BP 365/12) and emissions collected through a BP ﬁlter (480–520nm).
Values of intensity ﬂuorescence quantiﬁcation were performed using the Image J
software (NIH, Bethesda, MD, USA).
Protein extraction and western blot. H9c2 cells were washed twice with
ice-cold Buffer A (10mM Hepes, pH 7.9;. 1mM EDTA, 1mM EGTA, 10mM KCl,
1mM DTT, 0.5nM PMSF, 2mg/ml aprotinin, 10mg/ml leupeptin, 2mg/ml TLCK
(Na-tosyl-L-lysine chloromethyl ketone hydrochloride), 5mM NaF, 1mM NaVO4,
10mM Na2MoO4) containing 120mM NaCl and scraped off the plate. Cells were
lysed at 41C with 0.2ml of buffer A supplemented with 0.5% Nonidet P-40 with
continuous shaking. After centrifugation of the cell lysate the supernatant was
stored at  801C (cytosolic cell extract).
Native cardiomyocytes were homogenized using a hand-held blender in lysis buffer
containing (in mM): 50 Tris, 320 sucrose and 1 DTT, pH 7.0, plus a complete protease
andphosphataseinhibitorssolution. Thehomogenatewasspunat13000gfor10minat
41C and supernatants (total cell extract) were frozen and stored at  801C. Protein
content in both cases was assayed with the Bio-Rad protein reagent (Bio-Rad,
Alcobendas, Spain).
For Western Blot equal amounts of cytosolic protein lysates were separated in
10–15% sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) gel electrophoresis.
Thegels wereblottedonto aHybond-Pmembraneandincubatedwith theindicated
antibodies. Blots were developed by ECL according to the manufacturer’s
instructions. b-actin was used as a loading control.
Statistical analysis. All the values are expressed as mean±S.D. The
statistical signiﬁcance of differences between the means were determined with the
SPSS19software(SPSS,Chicago,IL,USA)forWindowsusingaone-wayanalysis
of variance followed by Bonferroni post-hoc test or Student’s t-test, as appropriate.
A P-value of less than 0.05 was considered to be signiﬁcant.
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